Skip to Content

MD Anderson Events

“RNAs as drugs and targets for treating cancer and clotting”

“RNAs as drugs and targets for treating cancer and clotting”

 SynopsisNucleic acid molecules have significant promise as drugs and as drug targets for treating a variety of diseases including cancer and thrombosis. I will describe our preclinical and clinical studies evaluating RNA aptamer-based therapeutics that target cancer cells and coagulation factors. In addition, I will describe our recent efforts to develop molecules that can scavenge extracellular nucleic acid-containaing DAMPs to combat inflammation, coagulation and metastasis in various disease models.   

Date: 11/29/17, 9am to 10:30am
Time: 11/29/17, 9am to 10:30am
Location: 4SCR1.1110
Format: Seminar/Conference
Speaker: Bruce Sullenger
Speaker Bio: The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.
Contact: Roseann Martinez - (713) 563-2718 - rmartinez@mdanderson.org